ArticleCancer science2026
Proportion of Screen-Detected Gastrointestinal Cancers From the National Cancer Registry in Japan.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, information on routes of diagnosis in cancer registration in Japan lacked reliability. The launch of the National Cancer Registry in 2016 produced a marked improvement in data accuracy. In this study, we aimed to estimate the proportion of screen-detected gastrointestinal cancers using the National Cancer Registry and to examine its correlation with cancer screening participation rates. We analyzed 2016-2020 National Cancer Registry data to identify screen-detected gastrointestinal cancers and assess the correlation between route of diagnosis and stage at diagnosis. Screening participation rates were extracted from the Comprehensive Survey of Living Conditions (CSLC) and the Report on Regional Public Health Services and Health Promotion Services via e-Stat, and their correlations with screen-detected cancer proportions were assessed using prefecture-level data. Screen-detected cancers accounted for 14.4% for esophageal cancer, 18.6% for gastric cancer, and 21.3% for colorectal cancer. Cancers detected through "other routes (including symptomatic detection)" accounted for 47.1%, 41.6%, and 45.1%, respectively. Screen-detected cases more frequently presented as intraepithelial or localized disease. In gastric and colorectal cancer, positive correlations were observed between the proportions of screen-detected cancers and screening participation rates; for example, correlation coefficients based on the 2019 CSLC were 0.61 for gastric cancer and 0.71 for colorectal cancer. Screen-detected gastrointestinal cancers accounted for roughly 20% of all detected routes. Higher screening rates were correlated with higher proportions of screen-detected cancers. These findings suggest that the proportion of screen-detected cancers may serve as an indicator of screening program quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.